Susquehanna International Group
RLMD icon

Susquehanna International Group’s Relmada Therapeutics RLMD Stock Holding History

Susquehanna International Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$326K Buy
+46,800
New +$221K ﹤0.01% 10692
2024
Q4 		– Sell
-12,200
Closed -$39.5K – 13052
2024
Q3 		$39.5K Buy
+12,200
New +$39.5K ﹤0.01% 11461
2024
Q1 		– Sell
-25,600
Closed -$106K – 13164
2023
Q4 		$106K Buy
25,600
+2,300
+10% +$6.81K ﹤0.01% 11283
2023
Q3 		$69.9K Sell
23,300
-26,800
-53% -$79.6K ﹤0.01% 11136
2023
Q2 		$123K Buy
50,100
+19,000
+61% +$52.5K ﹤0.01% 10763
2023
Q1 		$70.3K Buy
31,100
+10,800
+53% +$37.2K ﹤0.01% 11529
2022
Q4 		$70.8K Sell
20,300
-602,200
-97% -$5.29M ﹤0.01% 11208
2022
Q3 		$23M Buy
622,500
+380,300
+157% +$10.5M 0.01% 1310
2022
Q2 		$4.6M Buy
242,200
+207,400
+596% +$4.52M ﹤0.01% 3318
2022
Q1 		$939K Buy
34,800
+25,900
+291% +$536K ﹤0.01% 7289
2021
Q4 		$201K Buy
+8,900
New +$198K ﹤0.01% 11439
2021
Q3 		– Sell
-80,200
Closed -$2.57M – 13427
2021
Q2 		$2.57M Buy
80,200
+62,800
+361% +$2.18M ﹤0.01% 5365
2021
Q1 		$613K Buy
+17,400
New +$609K ﹤0.01% 9007
2020
Q3 		– Sell
-11,400
Closed -$510K – 11059
2020
Q2 		$510K Buy
+11,400
New +$482K ﹤0.01% 7318

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Susquehanna International Group's RLMD Position: Q1 2026 in Review

Susquehanna International Group increased its Relmada Therapeutics (RLMD) stake by 162% in Q1 2026, buying an estimated $2.96M and bringing the position to 1,011,572 shares worth $7.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3650.

Susquehanna International Group first reported a position in RLMD in Q4 2019 and has held it in 20 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Susquehanna International Group held 1,011,572 shares of Relmada Therapeutics worth $7.04M as of Q1 2026.
  • Susquehanna International Group bought 625,630 Relmada Therapeutics shares in Q1 2026, an estimated $2.96M.
  • Relmada Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3650 holding.
  • Susquehanna International Group first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.